WO1992015590A1

WO1992015590A1 - New meso-azacyclic aromatic acid amides and esters as novel serotonergic agents

Info

Publication number: WO1992015590A1
Application number: PCT/US1992/001525
Authority: WO
Inventors: Daniel P. Becker; Daniel L. Flynn; Alan Edward Moormann; Roger Nosal; Clara I. Villamil
Original assignee: GD Searle LLC
Current assignee: GD Searle LLC
Priority date: 1991-03-07
Filing date: 1992-03-04
Publication date: 1992-09-17
Anticipated expiration: 1993-09-07
Also published as: EP0528026A1; IE920751A1; US5318977A; AU1578692A; JPH05507942A; EP0504680A1; CA2082415A1; US5612366A

Abstract

Meso-azacyclic aromatic acid amides and esters of formula Ar-(CO-X)p-Z wherein Ar represents a radical of formulae (A, B) and when p is 1, Ar represents a radical of formulae (C, D, E, F, G, H) and Z represents a radical of formulae (I, J) are useful in the treatment of the central nervous system and gastrointestinal motility disorders such as gastroesophageal reflux, non-ulcer dyspepsia, delayed gastric emptying, ileus, irritable bowel syndrome, and the like. Additionally, they find utility as antagonists of serotonin 5-HT3 receptors, and are useful for the treatment of humans and animals wherein antagonism of 5-HT3 receptors is beneficial. Therapy is indicated for the treatment of anxiety, psychoses, depression (especially depression accompanied by anxiety), cognitive disorders, substance abuse dependence and/or withdrawal, irritable bowel syndrome, emesis caused by chemotherapeutic agents, and visceral pain. Additionally, they may find utility as enhancers of nasal absorption of bioactive compounds.

Description

New Meso-Azacyclic Aromatic Acid Amides and Esters as Novel Serotonergic Agents.

BACKGROUND OF THE INVENTION

The invention herein is directed to compounds and a method of treating gastrointestinal motility disorders of a mammal by administering to the mammal in need thereof a therapeutically effective amount of a compound disclosed herein or a pharmaceutically acceptable salt thereof. The method can be practiced to treat gastrointestinal motility disorders such as gastroesophageal reflux, diseases characterized by delayed gastric emptying, ileus,

irritable bowel syndrome, and the like. The compounds of the invention are serotonergic 5-HT₃ antagonists and as such are useful for the treatment of conditions, for example, such as anxiety, psychoses and depression.

There are classes of compounds known for the treatment of such disorders. For example, azatetracycle compounds are disclosed in co-pending U.S. patent application serial no. 07/515,391 filed April 27, 1990, and N-Azabicyclo [3.3.0] octane amides of aromatic acids are disclosed in copending application serial no. 07/406,205 filed September 11, 1989. Aza-adamantyl compounds are disclosed in U.S. Patent 4,816,453 and are mentioned generically in U.K. Patent 2,152,049A and European application 0189002A2.

Azabicyclic nonanes are disclosed in European Patent application 0094742A2. Additional azabicyclic compounds are disclosed in U.S. Patents 4,797,387 and 4,797,406.

Benzamides have been known as 5-HT₃ antagonists and as compounds possessing gastrointestinal motility-enhancing properties. Benzamides of the following formula:

compounds wherein X can be an azabicycloalkane moiety and which exhibit gastrointestinal motility enhancing and/or 5-HT₃ antagonist properties are disclosed in EP 0094742A2 and in U.S. patent 4,797,406. In addition, UK Patent 2,152,049 discloses that certain benzamide derivatives exhibit serotonin M antagonistic activity.

Indoleamides of the following formula have also been described as possessing gastrointestinal motility-enhancing and/or 5-HT₃ antagonist properties:

Compounds wherein X contains an aminergic side chain or an azabicycloalkane moiety are described in U.S. Patent

4,797,406.

European patent publication number 0,230,718 discloses certain substituted benzamide derivatives, substituted with piperidinyl analogues as having gastrointestinal motility-enhancing and/or antiemetic activity and/or 5-HT receptor antagonist activity.

J. Heterocyclic Chemistry (1987) 24 : 47 describes the preparation of the following compound: No substitution is shown in the phenyl ring and no utility is described.

J. Pharmaceutical Sciences (1987) 76: 416 describes compounds of generic scope. Utility as anti-arrhythmic agents is described.

n = 1 or 2

R₁ = H, 2-Me, 4-NH₂, 4-OMe, 4-NHCO₂Et, 2-OEt, 4-OEt, 3- or

4-NMe₂, 3- or 4-NO₂; R₂ = H or 6-Me.

JP Patent 58083694 A2 and JP 0027355B describe antiarrhythmic agents of the following formula wherein n = 1 or 2; R₁ or R₂ are both Me or R₁ is H while R₂ is nitro, di-lower alkylamino, lower alkoxycarbonylamino, or ethoxy.

EP Patent 39,903 and US 4,617,401 describe compounds of the following formula wherein R is H, OMe, OH, or NH₂; X is NH or O; and Z is a lone electron pair or optionally substituted alkyl group. The compounds are described as spasmolytic, antiarrhythmic, and neuromuscular-blocking agents.

SUMMARY OF THE INVENTION

The compounds of the present invention are useful in the treatment of gastrointestinal motility disorders such as gastroesophageal reflux, non-ulcer dyspepsia, delayed gastric emptying, ileus, irritable bowel syndrome, and the like. Additionally, the compounds of the present

invention find utility as antagonists of serotonin 5-HT₃ receptors. As such they are useful for the treatment of humans and animals wherein antagonism of 5-HT₃ receptors is beneficial. Therapy is indicated for, but not limited to, the treatment of anxiety, psychoses, depression

(especially depression accompanied by anxiety), cognitive disorders, substance abuse dependence and/or withdrawal, irritable bowel syndrome, emesis caused by

chemotherapeutic agents, and visceral pain. Additionally, the compounds of the present invention may find utility as enhancers of nasal absorption of bioactive compounds.

DETAILED DESCRIPTION OF THE INVENTION

The invention herein is directed to compounds of

formula I:

the stereoisomers and pharmaceutically acceptable salts thereof wherein p is 0 or 1 and when p is 0, Ar represents a radical of the formula:

and when p is 1, Ar represents a radical of the formula:

Wherein Y is NH; R₁ is C_1-6 alkoxy; R₂ and R₃ are

independently H, halogen, CF₃, hydroxyl, C_1-2 alkoxy, C_2-7 acyl, amino, amino substituted by one or two C_1-6 alkyl groups, C_2-7 acylamino, aminocarbonyl, or aminosulfone optionally substituted by one or two C_1-6 alkyl groups, C_1- ₆ alkylsulfone, or nitro; R₄ is H, halo, or C₁_₆ alkoxy; R₅ and R₆ are the same or different and can be H, halo, CF₃, C_1-6alkyl, C_1-6 alkoxy, C₁_₆ alkylthio, C₁_₇ acyl, C₁_₇ acylamino, C_1-6 alkylsulfonylamino, N-(C_1-6 alkylsulfonyl)- N-C_1-4 alkylamino, C_1-6 alkylsulfinyl, hydroxy, nitro, or amino, aminocarbonyl, aminosulfonyl, aminosulfonylamino, or N-(aminosulfonyl)-C_1-4 alkylamino optionally N'-substituted by one or two groups selected from C_1-6 alkyl, C_3-8 cycloalkyl, phenyl, or phenyl C_1-4 alkyl groups or optionally N'-disubstituted by C₄_₅ polymethylene; R₇ and R₁₀ can be the same or different and can be H, C_1-6 alkyl, C₂_₆ alkenyl, C_1-4 alkyl or together are C₂_₄ polymethylene; R₈ and R₉ can be the same or different and can be H, C_1-4 alkyl or taken together are a covalent bond; R₁₁ is H or halogen; R₁₂ and R₁₂' are the same or different and can be H, C₁_₆ alkyl, or phenyl C_1-4 alkyl; R₁₃ and R₁₄ can be the same or different and can be H, halo, CF₃, C₁_₆ alkyl, C_1-7 acyl, C_1-7 acylamino, or amino, aminocarbonyl or

aminosulfonyl, optionally substituted by one or two C₁_₆ alkyl or C₃_₈ cycloalkyl groups, or by C₄_₅ polymethylene or biphenyl, C_1-6 alkylsulfonyl, C_1-6 alkylsulfinyl, C_1-6 alkoxy, C_1-6 alkylthio, hydroxy, or nitro, or when R₁₃ and R₁₄ are taken together are methylenedioxy or ethylenedioxy; A₂ is O, S, N(R₁₂), or CH₂; A₂ is C-OR₁₂, N+╌O-, CO₂R₁₂ , CONR₁₂(R₁₂'), SR₁₂, or SO₂NR₁₂(R₁₂'); A₃ is N or CH;

X is NH or O; and

Z represents a radical of the formula:

Wherein m is 1 or 2, n is 0 or 1, p is 1 or 2, q is 1 or 2, and r is 0 or 1.

The term "cycloalkyl" embraces cyclic radicals having three to about ten ring carbon atoms, preferably three to about six carbon atoms, such as cyclopropyl and

cyclobutyl. The terms "alkoxy" and "alkoxyalkyl" embrace linear or branched oxy-containing radicals each having alkyl portions of one to about ten carbon atoms, such as methoxy group.

Specific examples of alkyl groups are methyl, ethyl, n- propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tertbutyl, n-pentyl, iso-pentyl, methyl-butyl, dimethylbutyl and neopentyl.

Included within the family of compounds of the described are the tautomeric forms of the described compounds, isomeric forms including diastereoisomers and individual enantiomers, and the pharmaceutically-acceptable salts thereof. The term "pharmaceutically-acceptable salts" embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. Since the compounds contain basic nitrogen atoms, such salts are typically acid addition salts. The phrase

"pharmaceutically-acceptable salts" is intended to embrace alkyl quaternary ammonium salts and n-oxides. The nature of the salt is not critical, provided that it is

pharmaceutically acceptable, and acids which may be employed to form such salts are, of course, well known to those skilled in this art. Examples of acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulfuric acid and phosphoric acid, and such organic acids as maleic acid, succinic acid and citric acid. Other pharmaceutically acceptable salts include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium and magnesium, or with organic bases, such as dicyclohexylamine. All of these salts may be prepared by conventional means by reacting, for example, the appropriate acid or base with the corresponding compound of the invention.

The compounds that are the subject of the invention herein can be prepared according to the following reaction schemes.

Z₁ is known and is prepared as described by Miyano and coworkers [J. Heterocyclic Chemistry (1987) 24, 47 for q = 1; J. Pharmaceutical Sciences (1987), 76, 416 & references sited therein]. Z₂ is prepared according to schemes 1, 2, and 3.

Scheme 1 describes the preparation of amino-azacycles Z₂. The BOC-amine 1 (U.S. Patent Application serial no.

07/515,391) is deprotected with trifluoroacetic acid and the resulting amine is cyclized intramolecularly with the exocyclic olefin by treatment with iodine and potassium iodide in the presence of sodium bicarbonate to yield the bridgehead iodide 2. Treatment of 2 with silver

isocyanate affords the bridgehead isocyanate which may be hydrolyzed to give the requisite amine Z₂ wherein r = 0. Alternatively treatment of 2 with silver cyanide affords the bridgehead nitrile which may be reduced to give the desired aminomethyl-azacycle Z₂ wherein r = 1.

Scheme 2 illustrates the preparation of Z₂ hydroxy

azacycles. Hydrolysis of bridgehead iodide 2 affords the desired hydroxy azacycle Z₂,, wherein r = 0. Alternatively treatment of 2 with silver cyanade followed by hydrolysis and reduction gives the desired hydroxymethyl azacycle Z₂,,, wherein r = 1. Scheme 3 illustrates the preparation of ethano-bridged azatricycles (Z₂,,,,, wherein m = 2). The azabicycloketone 3 is converted first to its O-benzyloxime. Removal of the N-BOC protecting group, followed by acylation with

chloroacetic anhydride & iodide exchange, affords the intermediate 4. Cyclization under reductive radicalcyclization conditions (Bu₃SnH, AIBN) affords the ethano-bridged lactam 5. Reduction with lithium aluminum hydride affords the desired ethano-bridged azatricycle Z₂,,,.

SCHEME 1: PREPARATION OF Z₂ AMINO-AZACYCLES

SCHEME 2: PREPARATION OF Z₂ HYDROXY AZACYCLES

SCHEME 3 : PREPARATION OF ETHANO-BRIDGED

MESO-AZATRICYCLE

These examples, as well as all examples herein, are given by way of illustration only and are not to be construed as limiting the invention, either in spirit or scope, as many modifications, both in materials and methods, will be apparent from this disclosure to those skilled in the art. In these examples, temperatures are given in degrees

Celsius (°C) and quantities of materials in grams and milliliters unless otherwise noted.

EXPERIMENTALS

EXAMPLE A

Preparation of hexahydro-5-iodo-2,5β-methano-1H-3aα,6aα-cyclopenta[c]pyrrole

Cis-N-t-butoxycarbonylhexahydro-5-methylenecyclopenta[c]pyrrole [See co-pending Application Serial No. 07/515,391 filed April 27, 1990] is treated with trifluoroacetic acid to afford an intermediate trifluoroacetate ammonium salt, which is then treated with base and I₂ to afford the title compound.

EXAMPLE B

Preparation of tetrahydro-2,50-methano-1H-3aα,6aα-cyclopenta[c]pyrrol-5(3H)-amine

The iodo compound prepared in example A is treated with silver isocyanate to afford the intermediate N-formamide, This formamide is hydrolyzed to give the title compound.

EXAMPLE C

Preparation of tetrahydro-2,5β-methano-1H-3aα,6aα- cyclopenta[c]pyrrole-5(3H)-carbonitrile

The iodo compound prepared in example A is treated with silver cyanide in dimethylformamide to afford the title compound.

EXAMPLE D

Preparation of tetrahydro-2 ,5β-methano-1H-3aα , 6aα-cyclopenta[c]pyrrole-5 (3H) -methanamine

The nitrile compound prepared in example C is reduced with lithium aluminum hydride in etheral solvent to afford the title compound.

EXAMPLE E

Preparation of tetrahydro-2,5β-methano-1H-3aα,6aα-cyclopenta[c]pyrrole-5(3H)-methanol

The nitrile compound prepared in example C is converted to the intermediate ethyl ester by treatment with aqueous ethanolic HCI. The ethyl ester is then treated with lithium aluminum hydride in etheral solvent to afford the title compound.

EXAMPLE F

Preparation of 1,1-dimethylethyl hexahydro-5-[(phenylmethoxy)imino]cyclopenta[c]pyrrole-2(1H)

carboxylate

Cis-N-Butoxycarbonylhexahydro-5-oxo-cyclopenta[c]pyrrole is reacted with O-benzylhydroxylamine hydrochloride and sodium acetate in methanol to afford the title compound. EXAMPLE G

Preparation of octahydro-2-(iodoacetyl)-5- [(phenylmethoxy)imino]cyclopenta[c]pyrrole

The title compound of example F is treated with

trifluoroacetic acid in methylene chloride at room temperature. The volatiles are removed under reduced pressure to afford a residue which is treated with chloroacetic anhydride and triethylamine. The

chloroacetylated material is then reacted with Nal in acetone to give the title compound.

EXAMPLE H

Preparation of hexahydro-5- [ (phenylmethoxy) amino]- 2,5β-ethano-1H-3aα, 6aα-cyclopenta [c]pyrrol-7-one

The title compound of example G is treated with tri-n-butylstannane in benzene at reflux containing a catalytic amount of AIBN. Upon workup the title compound is isolated. EXAMPLE J

Preparation of tetrahydro-2,5β-ethano-1H-3aα,6aα-cyclopenta[c]pyrrol-5(3H)-amine

The title compound of example H is reacted with lithium aluminum hydride in tetrahydrofuran to afford after workup the title compound.

EXAMPLE 1

Preparation of 4-amino-5-chloro-2-methoxy-N-(tetrahydro- 1H-pyrrolizin-7a(5H)-ylmethyl)benzamide

4-Amino-5-chloro-2-methoxybenzoic acid (134 mg, 0.00095 moles) and 1,1'-carbonyldi-imidazole (151 mg, 0.00095 moles) were suspended in the DMF (2.5 ml) and the mixture was stirred until solution occurred (three hours). At this time, tetrahydro-1H-pyrrolizin-7a(5H)-methylamine

[amine J. Het Chem 24, 47, 1987] (134 mg; 0.00095 moles) was added and the mixture was stirred for 2 hours. Tlc 30% MeOH/CHCl₃/1/10% NH₄OH indicated that the reaction was complete. Concentration afforded a residue which was purified by prep tic chromatography, eluting with 15% MeOH/CHCl₃/1/10% NH₄OH to yield 73 mg (24%) of the product. The residue was converted to the HCI salt with MeOH/HCl.

Elements Calc Found

Carbon 53.63 53.57 C₁₆H₂₂ClN₃O₂ * 0.7 HCl * 0.5 H2O

Hydrogen 6.67 6.66

Nitrogen 11.73 11.54 MW 358.35

Chlorine 16.82 16.51

Example 1A

4-Amino-5-chloro-2-methoxy-N-(tetrahydro-1H-pyrrolizin- 7a(5H)-ylethyl)benzamide

Procedure

4-Amino-5-chloro-2-methoxybenzoic acid (1.0 g, 0.005 moles) and 1,1'-carbonyldi-imidazole (892 mg, 0.00055 moles) were suspended in the DMF (10 ml) and the mixture was stirred until solution occurred (three hours). At this time, tetrahydro-1H-pyrrolizin-7a(5H)-ethylamine

[amine Heterocycles 16, 755, 1981] (771 mg; 0.005 moles) was added and the mixture was stirred for 1 hour. Tlc 30% MeOH/CHCl₃/l/10% NH₄OH indicated that the reaction was complete. Concentration afforded a residue which was partitioned between Et₂O/H₂O. The product crystallized. The solid was filtered and dissolved in CHCl₃, washed with dilute K₂CO₃, dried over MgSO₄ and concentrated to a solid. The solid was triturated with Et₂O and converted to the HCI salt with MeOH/HCl to yield 1.27g (69%) of the

product.

Elements

Carbon 49.71 49.39 C₁₇H₂₄ClN₃O₂ * 2 HCI

Hydrogen 6.38 6.46

Nitrogen 10.23 10.18 MW 410.77

Chlorine 25.89 25.71

Example 1B

N'-(tetrahydro-1H-pyrrolizin-7a(5H)-ylmethyl)-2- (2-propyloxy)phenylurea

2-isopropoxy-aniline (123 mg, .813 mmole) was

dissolved in CHCl₃ (1 ml), added triethyl amine (.113 ml, .813 mmole). Cooled soln. to 0°C, added a solution of 20%. phosgene in toluene (.458 ml, .927 mmole) and stirred for 1.5 hours. To this solution was added tetrahydro-1H-pyrrolizin-7a(5H)-methylamine (114 mgs, .813 mmole) in CHCl₃ and stirred for 18 hours. Solvent removed via rotary evaporator to give crude product as a solid. Solid was chromatographed on silica gel eluting with 5%

CH₃OH(NH₃†)/CHCl₃ to give 220 mg (85%) of title compound as free base.

Calculated for C₁₈H₂₇N₃O₂. Found

C, 67 .89 67.96

H, 8.86 8.61

N, 13. 19 12.96

Calculated MS for C₁₈H₂₃N₃O₂ = 318.44

Found M = 318.215

EXAMPLE 2

Preparation of N-(tetrahydro-1H-pyrrolizin-7a(5H)-ylmethyl)-1H-indole-3-carboxamide

Following the procedure of example 1, 7a-Aminomethylhexahydro-1H-pyrrolizine is reacted with indole-3-carboxylic acid to afford the title compound.

Indole-3-carboxylic acid (161 mg, 0.001 moles) and 1,1-carbonyldiimidazole (162 mg, 0.001 moles) were suspended in the DMF (2.5 ml) and the mixture was stirred until solution occurred (three hours). At this time,

tetrahydro-1H-pyrrolizin-7a(5H)-methylamine [amine J. Het Chem 24, 47, 1987] (140 mg; 0.001 moles) and triethylamine (560 μl; 0.004 mole) were added and the mixture was stirred for 1 hour. Tlc 30% EtOH/CHCl₃/1/10% NH₄OH indicated that the reaction was complete. Concentration afforded a residue that was partitioned between Et₂O/H₂O. The product crystallized. The solid was filtered and dissolved in CHCl₃, washed with dilute NaOH, dried over MgSO₄ and concentrated to a solid. The solid was

triturated with Et₂O and converted to the HCI salt with MeOH/HCl to yield 174 mg (62%) of the product.

Elements Calc Found

Carbon 62 . 98 62 . 68 C₁₇H₂₁N₃O * 0. 75 HCI * 0. 75 H₂O

Hydrogen 7.23 6.68

Nitrogen 12.96 12.96 MW 324.23

Chlorine 8.20 8.31

SUBSTITUTE SHEET EXAMPLE 3

Preparation of 2,3-dihydro-N-(tetrahydro-1H-pyrrolizin- 7a(5H)-ylmethyl)-1H-indole-1-carboxamide

7a-Aminomethylhexahydro-1H-pyrrolizine is reacted with indoline-N-trichloromethylcarbamate [J. Medicinal

Chemistry (1990) 33: 1929] in toluene at reflux to afford the title compound after extractive workup and column chromatography.

EXAMPLE 4

Preparation of 1-methyl-N-(tetrahydro-1H-pyrrolizin-7a(5H)-ylmethyl)-1H-indazole-3-carboxamide

Following the procedure of example 1, 7a-Aminomethylhexahydro-1H-pyrrolizine is reacted with N-methylindazole-3-carboxylic acid [J. Medicinal Chemistry (1987) 30: 1535] to afford the title compound. EXAMPLE 5

Preparation of 4-amino-5-chloro-2-methoxy-N- (tetrahydro-2 ,5β-methano-1H-3aα , 6aα-cyclopenta [ c ] pyrrol-5 ( 3H) -yl) benzamide

N-hexahydro-1H-2,5β-methano-3aα,6aα-cyclopenta[c]pyrrol-5α-amine is reacted with 2-methoxy-4-amino-5-chlorobenzoic acid and carbonyldiimidazole in dimethylformamide to afford the title compound.

EXAMPLE 6

Preparation of N-(tetrahydro-2,5β-methano-1H-3aα,6aα-cyclopenta[c]pyrrol-5(3H)-yl)-1H-indole-3-carboxamide

N-hexahydro-1H-2,5β-methano-3aα,6aα-cyclopenta[c]pyrrol-5α-amine is reacted with indole-3-carboxylic acid

according to the procedure of example 5 to afford the title compound. EXAMPLE 7

Preparation of 1-methyl-N-(tetrahydro-2,5β-methano-1H- 3aα,6aα-cyclopenta[c]pyrrol-5(3H)-yl)-1H-indazole-3- carboxamide

N-hexahydro-1H-2,5β-methano-3aα,6aα-cyclopenta[c]pyrrol- 5α-amine is reacted with N-methylindazole-3-carboxylic acid according to the procedure of example 5 to afford the title compound.

EXAMPLE 8

Preparation of 2,3-dihydro-N-(tetrahydro-2,5β-methano-1H-3aα,6aα-cyclopenta[c]pyrrol-5(3H-yl)-1H-indole-3-carboxamide

N-hexahydro-1H-2,5β-methano-3aα,6aα-cyclopenta[c]pyrrol-5α-amine is reacted with indoline-N-trichloromethylcarbamate according to the procedure of example 3 to afford the title compound. The compounds herein exhibit 5-HT3 antagonism. 5-HT3 antagonism can be determined by the radioligand receptor binding assay as described herein and in the in vivo Bezold-Jarisch reflex procedure.

Serotonin (5-HT₃)

Procedure:

GR65630 binds to the 5-HT₃ receptor. Brain cortices are obtained from male rats and a membrane fraction prepared by standard techniques. 0.04 mg of membrane prep is incubated with 0.2 nM [³H]-GR656630 for 60 minutes at 22°C. Non-specific binding is estimated in the presence of 1 uM ICS 205-930. Membranes are filtered and washed 3 times and the filters are counted to determine [3H]- GR65630 specifically bound.*

Results:

Kd = 2.46 nM

Bmax = 154 fmol/mg protein

% Specific Binding: 70

*Literature Reference:

Kilpatrick GJ, Jones BJ and Tyers MB. Identification and distribution of 5-HT₃ receptors in rat brain using

radioligand binding. Nature, 330 : 746-748, 1987. Bezold-Jarisch Reflex

The test sample is administered i.p. (mg/kg) to a group of 3 mice. Thirty minutes later, a 5-HT (0.25 mg/kg i.v.)-induced bradycardia is recorded in pentobarbital

anesthetized animals. A greater than 50 percent (>50) reduction in the bradycardic response relative to vehicle-treated control mice is considered significant.

REFERENCE AGENTS: Minimum Effective Dose

(MED) mg/kg

BRL-43694 0.05

cisapride 5 cyproheptadine 5 domperidone >10

GR-38032 0.5

ketanserin >10

mecamylamine 2.5

methysergide >10

metoclopramide 5 scopolamine 2.5

This method has been described by Saxena, P. R. and

Lawang, A., Arch. Int. Pharmacodyn., 277: 235-252, 1985.

Also embraced within this invention is a class of

pharmaceutical compositions comprising one or more of the described compounds in association with one or more non- toxic, pharmaceutically acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as "carrier" materials) and, if desired, other active ingredients. The compounds of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. Therapeutically effective doses of the compounds of the present invention required to prevent or arrest the progress of the medical condition are readily ascertained by one of ordinary skill in the art. The compounds and composition may, for example, be administered

intravascularly, intraperitoneally, subcutaneously, intramuscularly or topically.

For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. Examples of such dosage units are tablets or capsules. These may with advantage contain an amount of active ingredient from about 1 to 250 mg, preferably from about 25 to 150 mg. A suitable daily dose for a mammal may vary widely depending on the condition of the patient and other factors.

However, a dose of from about 0.1 to 3000 mg/kg body weight, particularly from about 1 to 100 mg/kg body weight, may be appropriate.

For therapeutic purposes, the compounds of this invention are ordinarily combined with one or more adjuvants

appropriate to the indicated route of administration. If administered per os, the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be

provided in a dispersion of active compound in

hydroxypropylmethyl cellulose. Formulations for

parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of

administration are well and widely known in the

pharmaceutical art. Although this invention has been described with respect to specific embodiments, the details of these embodiments are not to be construed as limitations. Various equivalents, changes and modifications may be made without departing from the spirit and scope of this invention, and it is understood that such equivalent embodiments are part of this invention.

Claims

What is Claimed is:

1. A compound of the formula

Ar-(CO-X)p-Z the stereoisomers and pharmaceutically acceptable salts thereof, wherein p is 0 or 1 and when p is 0, Ar represents a radical of the formula

and when p is 1, Ar represents a radical of the formula

Wherein Y is NH, R₁ is C₁_₆ alkoxy, R₂ and R₃ are

independently H, halogen, CF₃, hydroxyl, C₁_₂ alkoxy, C₂_₇ acyl, amino, amino substituted by one or two C₁_₆ alkyl groups, C₂_₇ acylamino, aminocarbonyl, or aminosulfone optionally substituted by one or two C₁_₆ alkyl groups,

C₁_₆ alkylsulfone, or nitro, R₄ is H, halogen, or C₁_₆ alkoxy; R₅ and R₆ are the same or different and can be H, halogen, CF₃, C₁_₆ alkyl, C₁_₆ alkoxy, C₁_₆ alkylthio, C₁_₇ acyl, C₁_₇ acylamino, C₁_₆ alkylsulfonylamino, N-(C₁_₆ alkylsulfonyl)-N-C₁_₄ alkylamino, C₁_₆ alkylsulfinyl, hydroxy, nitro, or amino, aminocarbonyl, aminosulfonyl, aminosulfonylamino, or N-(aminosulfonyl)-C₁_₄ alkylamino optionally N'-substituted by one or two groups selected from C₁_₆ alkyl, C₃_₈ cycloalkyl, phenyl or phenyl C_1-4 alkyl groups optionally N'-disubstituted by C₄_₅

polymethylene, R₇ and R₁₀ can be the same or different and can be H, C₁_₆ alkyl, C₂_₆ alkenyl, C₁_₄ alkyl or together _are C₂_₄ polymethylene, R₈ and R₉ can be the same or different and can be H, C₁_₄ alkyl or taken together are a covalent bond, R₁₁ is H or halogen, R₁₂ and R₁₂' are the same or different and can be H, C₁_₆ alkyl, or aralkyl, R₁₃ and R₁₄ can be the same or different and can be H, halogen,

CF₃, C₁_₆ alkyl, C₁_₇ acyl, C₁_₇ acylamino, or amino,

E aminocarbonyl or aminosulfonyl optionally substituted by one or two C_1-6 alkyl or C₃_₈ cycloalkyl groups, or by C₄_₅ polymethylene or biphenyl, C_1-6 alkylsulfonyl, C_1-6 alkylsulfinyl, C_1-6 alkoxy, C₁_₆ alkylthio, hydroxy, or nitro, or when R₁₃ and R₁₄ are taken together are

methylenedioxy or ethylenedioxy;

Al is O, S, N(R₁₂), or CH₂; A₂ is C-OR₁₂, N+╌O-, CO₂R₁₂, CONR₁₂(R₁₂'), SR₁₂, or SO₂NR₁₂(R₁₂'); A₃ is N or CH;

X is NH or O; and

Z represents a radical of the formula

Wherein m is 1 or 2, n is 0 or 1, p is 1 or 2, q is 1 or 2 and r is 0 or 1.

2. A compound according to claim l wherein p is 0.

3. A compound according to claim 2 wherein Ar is group A.

4. A compound according to claim 3 wherein Z is Z₁.

5. A compound according to claim 3 wherein Z is Z₂

6. A compound according to claim 1 wherein p is 1.

7. A compound according to claim 6 wherein Ar is group C.

8. A compound according to claim 7 wherein Z is Z₁.

9. A compound according to claim 7 wherein Z is Z₂.

10. A compound according to claim 7 wherein Ar is

2-chloro-5-methoxyanilin-4-yl.

11. A compound according to claim 10 wherein Z is Z₁.

12. A compound according to claim 10 wherein Z is Z₂.

13. A compound according to claim 6 wherein Ar is

group D.

14. A compound according to claim 13 wherein Z is Z₁.

15. A compound according to claim 13 wherein Z is Z₂.

16. A compound according to claim 13 wherein Ar is indol-3-yl.

17. A compound according to claim 16 wherein Z is Z₁.

18. A compound according to claim 16 wherein Z is Z₂.

19. A compound according to claim 6 wherein Ar is

group E.

20. A compound according to claim 19 wherein Z is Z₁.

21. A compound according to claim 19 wherein Z is Z₂.

22. A compound according to claim 6 wherein Ar is

group H.

23. A compound according to claim 22 wherein Z is Z₁.

24. A compound according to claim 22 wherein Z is Z₂.

25. A pharmaceutical composition for the treatment of anxiety, psychoses, depression, gastrointestinal motility disturbancies or conditions response to 5-HT₃ antagonist effect comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier or diluent.

26. A pharmaceutical composition according to Claim 25 wherein the compound is selected from the group wherein Ar is group A, C, D, E or H; Z is Z₁ or Z₂; and p is 0 or 1.

27. A pharmaceutical composition according to Claim 26 wherein Ar is group C and p is 1.

28. A pharmaceutical composition according to Claim 27 wherein Ar is 2-chloro-5-methoxyanilin-4-yl.

29. A pharmaceutical composition according to Claim 26 wherein Ar is group D, and p is 1.

30. A pharmaceutical composition according to Claim 29 wherein Ar is indol-3-yl.